全文获取类型
收费全文 | 3208篇 |
免费 | 145篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 82篇 |
儿科学 | 133篇 |
妇产科学 | 62篇 |
基础医学 | 266篇 |
口腔科学 | 64篇 |
临床医学 | 241篇 |
内科学 | 628篇 |
皮肤病学 | 23篇 |
神经病学 | 233篇 |
特种医学 | 189篇 |
外科学 | 597篇 |
综合类 | 99篇 |
预防医学 | 135篇 |
眼科学 | 235篇 |
药学 | 179篇 |
中国医学 | 13篇 |
肿瘤学 | 180篇 |
出版年
2023年 | 20篇 |
2022年 | 63篇 |
2021年 | 129篇 |
2020年 | 49篇 |
2019年 | 76篇 |
2018年 | 112篇 |
2017年 | 79篇 |
2016年 | 88篇 |
2015年 | 78篇 |
2014年 | 124篇 |
2013年 | 162篇 |
2012年 | 260篇 |
2011年 | 252篇 |
2010年 | 156篇 |
2009年 | 153篇 |
2008年 | 184篇 |
2007年 | 176篇 |
2006年 | 142篇 |
2005年 | 170篇 |
2004年 | 134篇 |
2003年 | 110篇 |
2002年 | 125篇 |
2001年 | 55篇 |
2000年 | 37篇 |
1999年 | 41篇 |
1998年 | 18篇 |
1997年 | 13篇 |
1996年 | 10篇 |
1995年 | 6篇 |
1993年 | 14篇 |
1992年 | 23篇 |
1991年 | 31篇 |
1990年 | 27篇 |
1989年 | 34篇 |
1988年 | 21篇 |
1987年 | 22篇 |
1986年 | 12篇 |
1985年 | 9篇 |
1984年 | 11篇 |
1983年 | 12篇 |
1981年 | 19篇 |
1979年 | 6篇 |
1977年 | 7篇 |
1976年 | 9篇 |
1975年 | 8篇 |
1974年 | 6篇 |
1973年 | 10篇 |
1972年 | 6篇 |
1971年 | 7篇 |
1969年 | 6篇 |
排序方式: 共有3359条查询结果,搜索用时 31 毫秒
101.
102.
Aurélie Mbeutcha Ilaria Lucca Vitaly Margulis Jose A. Karam Christopher G. Wood Michela de Martino Romain Mathieu Andrea Haitel Evanguelos Xylinas Luis Kluth Morgan Rouprêt Pierre I. Karakiewicz Alberto Briganti Michael Rink Malte Rieken Alon Z. Weizer Jay D. Raman Nathalie Rioux-Leclecq Christian Bolenz Karim Bensalah Yair Lotan Christian Seitz Mesut Remzi Shahrokh F. Shariat Tobias Klatte 《World journal of urology》2016,34(8):1155-1161
Background
Excision repair cross-complementing 1 (ERCC1) has been associated with outcomes of urothelial carcinoma of the bladder, but was not yet studied in upper tract urothelial carcinoma (UTUC). The aim of this study was to assess the prognostic role of ERCC1 expression in a large international cohort of UTUC patients.Methods
Immunohistochemical ERCC1 expression was evaluated in 716 UTUC patients who underwent radical nephroureterectomy with curative intent. ERCC1 was considered positive when the H-score was >1.0. Associations with overall survival and cancer-specific survival were assessed using univariable and multivariable Cox models.Results
ERCC1 was expressed in 303 tumors (42.3 %) and linked with the presence of tumor necrosis (16.2 vs. 10.4 %, p = 0.023), but not with any other clinical or pathological variable. ERCC1 status did not predict cancer-specific survival and overall survival on both univariable (p = 0.70 and 0.32, respectively) and multivariable analyses (p = 0.48 and 0.33, respectively).Conclusions
ERCC1 is expressed in a significant proportion of UTUC and is linked with tumor necrosis, but its expression appears not to be associated with prognosis following radical nephroureterectomy.103.
Muddassir Mehmood Stephanie A. Ambach Michael D. Taylor John L. Jefferies Subha V. Raman Robin J. Taylor Hemant Sawani Jacob Mathew Wojciech Mazur Kan N. Hor Hussein R. Al-Khalidi 《Pediatric cardiology》2016,37(5):878-883
The relationship between pulmonary function and right ventricle (RV) in Duchenne muscular dystrophy (DMD) has not been evaluated. Using cardiac magnetic resonance (CMR), we describe the relationship of RV size and function with spirometry in a DMD cohort. Fifty-seven boys undergoing CMR and pulmonary function testing within 1 month at a single center (2013–2015) were enrolled. Comparisons of RV ejection fraction (RVEF) and end-diastolic volume index (RVEDVI) were made across categories of percent forced vital capacity (FVC%), and relationships were assessed. Mean age was 15.5 ± 3.5 years. Spirometry and CMR were performed within 3.9 ± 4.1 days. Median FVC% was 92.0 % (67.5–116.5 %). Twenty-three (40 %) patients had abnormal FVC% (<80 %) of which 13 (57 %) had mild (FVC% 60–79 %), 6 (26 %) had moderate (FVC% 40–59 %), and 4 (17 %) had severe (FVC <40 %) reductions. Mean RVEF was 58.3 ± 3.7 %. Patients with abnormal FVC% were older and had lower RVEF and RVEDVI. Both RVEF and RVEDVI were significantly associated with FVC% (r = 0.31, p = 0.02 and r = 0.39, p = 0.003, respectively). In a large DMD cohort, RVEF and RVEDVI were related to FVC%. Worsening respiratory status may guide monitoring of cardiac function in these patients. 相似文献
104.
Jennifer L. Williams Brian E. Kadera Andrew H. Nguyen V. Raman Muthusamy Zev A. Wainberg O. Joe Hines Howard A. Reber Timothy R. Donahue 《Journal of gastrointestinal surgery》2016,20(7):1331-1342
Background
Compared to the widely adopted 2–4 months of pre-operative therapy for patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC), our institution tends to administer a longer duration before considering surgical resection. Using this unique approach, the aim of this study was to determine pre-operative variables associated with survival.Methods
Records from patients with BR/LA PDAC who underwent attempt at surgical resection from 1992–2014 were reviewed.Results
After a median duration of 6 months of pre-operative treatment, 109 patients with BR/LA PDAC (BR 63, LA 46) were explored; 93 (85.3 %) underwent pancreatectomy. Those who received at least 6 months of pre-operative treatment had longer median overall survival (OS) than those who received less (52.8 vs. 32.1 months, P?=?0.044). On multivariate analysis, pre-operative treatment duration was the strongest predictor of survival (hazard ratio (HR) 4.79, P?=?0.043). However, OS was similar in those whose CA19-9 normalized regardless of whether they received more or less than 6 months of chemotherapy (71.4 vs. 101.8 months, P?=?0.930).Conclusions
Pre-operative CA19-9 decline can guide treatment duration in patients with BR/LA PDAC. We endorse 6 months of therapy except in those patients whose values normalize, where surgery can be considered after a shorter course.105.
106.
Reply to Tait,Alan; Voepel‐Lewis,Terri; Christensen,Robert; O'Brien,Louise, regarding their comment on ‘Utility of screening questionnaire,obesity, neck circumference,and sleep polysomnography to predict sleep‐disordered breathing in children and adolescents’
下载免费PDF全文
![点击此处可从《Paediatric anaesthesia》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Vidya T. Raman Mark Splaingard Dmitry Tumin Julie Rice Kris R. Jatana Joseph D. Tobias 《Paediatric anaesthesia》2016,26(10):1028-1029
107.
108.
Novel cardiovascular magnetic resonance oxygenation approaches in understanding pathophysiology of cardiac diseases
下载免费PDF全文
![点击此处可从《Clinical and experimental pharmacology & physiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Karthigesh Sree Raman Gaetano Nucifora Joseph B Selvanayagam 《Clinical and experimental pharmacology & physiology》2018,45(5):475-480
Cardiovascular magnetic resonance imaging (CMR) permits accurate phenotyping of many cardiac diseases. CMR’s inherent advantages are its non‐invasive nature, lack of ionizing radiation and high accuracy and reproducibility. Furthermore, it is able to assess many aspects of cardiac anatomy, structure and function. Specifically, it can characterize myocardial tissue, myocardial function, myocardial mass, myocardial blood flow/perfusion, irreversible and reversible injury, all with a high degree of accuracy and reproducibility. Hence, CMR is a powerful tool in clinical and pre‐clinical research. In recent years there have been novel advances in CMR myocardial tissue characterization. Oxygenation‐sensitive CMR (OS‐CMR) is a novel non‐invasive, contrast independent technique that permits direct quantification of myocardial tissue oxygenation, both at rest and during stress. In this review, we will address the principles of the OS‐CMR technique, its recent advances and summarize the studies in the effects of oxygenation on cardiac diseases. 相似文献
109.
Cheryl T. Lee Sam S. Chang Ashish M. Kamat Gilad Amiel Timothy L. Beard Amr Fergany R. Jeffrey Karnes Andrea Kurz Venu Menon Wade J. Sexton Joel W. Slaton Robert S. Svatek Shandra S. Wilson Lee Techner Richard Bihrle Gary D. Steinberg Michael Koch 《European urology》2014
Background
Radical cystectomy (RC) for bladder cancer is frequently associated with delayed gastrointestinal (GI) recovery that prolongs hospital length of stay (LOS).Objective
To assess the efficacy of alvimopan to accelerate GI recovery after RC.Design, setting, and participants
We conducted a randomized double-blind placebo-controlled trial in patients undergoing RC and receiving postoperative intravenous patient-controlled opioid analgesics.Intervention
Oral alvimopan 12 mg (maximum: 15 inpatient doses) versus placebo.Outcome measurements and statistical analysis
The two-component primary end point was time to upper (first tolerance of solid food) and lower (first bowel movement) GI recovery (GI-2). Time to discharge order written, postoperative LOS, postoperative ileus (POI)-related morbidity, opioid consumption, and adverse events (AEs) were evaluated. An independent adjudication of cardiovascular AEs was performed.Results and limitations
Patients were randomized to alvimopan (n = 143) or placebo (n = 137); 277 patients were included in the modified intention-to-treat population. The alvimopan cohort experienced quicker GI-2 recovery (5.5 vs 6.8 d; hazard ratio: 1.8; p < 0.0001), shorter mean LOS (7.4 vs 10.1 d; p = 0.0051), and fewer episodes of POI-related morbidity (8.4% vs 29.1%; p < 0.001). The incidence of opioid consumption and AEs or serious AEs (SAEs) was comparable except for POI, which was lower in the alvimopan group (AEs: 7% vs 26%; SAEs: 5% vs 20%, respectively). Cardiovascular AEs occurred in 8.4% (alvimopan) and 15.3% (placebo) of patients (p = 0.09). Generalizability may be limited due to the exclusion of epidural analgesia and the inclusion of mostly high-volume centers utilizing open laparotomy.Conclusions
Alvimopan is a useful addition to a standardized care pathway in patients undergoing RC by accelerating GI recovery and shortening LOS, with a safety profile similar to placebo.Patient summary
This study examined the effects of alvimopan on bowel recovery in patients undergoing radical cystectomy for bladder cancer. Patients receiving alvimopan experienced quicker bowel recovery and had a shorter hospital stay compared with those who received placebo, with comparable safety.Trial registration
ClinicalTrials.gov identifier NCT00708201 相似文献110.